{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Autologous+Genetically+modified+T+cells&page=3", "query": { "intervention": "Autologous Genetically modified T cells", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 88, "total_pages": 9, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Autologous+Genetically+modified+T+cells&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Autologous+Genetically+modified+T+cells&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-05T06:45:57.119Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03247309", "title": "TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Cancer", "Recurrent Solid Tumors", "Refractory Solid Tumors" ], "interventions": [ { "name": "IMA201 Product", "type": "BIOLOGICAL" }, { "name": "IMADetect®", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "BIOLOGICAL", "DIAGNOSTIC_TEST" ], "sponsor": "Immatics US, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2018-12-19", "completion_date": "2023-09-18", "has_results": false, "last_update_posted_date": "2025-02-04", "last_synced_at": "2026-10-05T06:45:57.119Z", "location_count": 2, "location_summary": "Pittsburgh, Pennsylvania • Houston, Texas", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03247309" }, { "nct_id": "NCT01653717", "title": "CD19-specific T-cell for Chronic Lymphocytic Leukemia (CLL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancers", "Leukemia" ], "interventions": [ { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "T-cell Infusion", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 30, "start_date": "2013-06-11", "completion_date": "2017-08-07", "has_results": false, "last_update_posted_date": "2017-08-17", "last_synced_at": "2026-10-05T06:45:57.119Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01653717" }, { "nct_id": "NCT05312411", "title": "A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-E2) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Osteosarcoma" ], "interventions": [ { "name": "SCRI-E2CAR_EGFRtv1", "type": "BIOLOGICAL" }, { "name": "UB_TT170", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Seattle Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "15 Years to 30 Years" }, "enrollment_count": 21, "start_date": "2022-05-20", "completion_date": "2040-05", "has_results": false, "last_update_posted_date": "2025-11-20", "last_synced_at": "2026-10-05T06:45:57.119Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05312411" }, { "nct_id": "NCT01683279", "title": "A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B Cell Leukemia" ], "interventions": [ { "name": "Autologous CD19 CAR+ EGFTt + T cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Seattle Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "26 Years", "sex": "ALL", "summary": "1 Year to 26 Years" }, "enrollment_count": 6, "start_date": "2012-03-25", "completion_date": "2030-01-07", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-10-05T06:45:57.119Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01683279" }, { "nct_id": "NCT03139370", "title": "Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "KITE-718", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "MAGE - A3/A6 Screening Test", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Kite, A Gilead Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2017-12-27", "completion_date": "2023-06-04", "has_results": false, "last_update_posted_date": "2023-08-25", "last_synced_at": "2026-10-05T06:45:57.119Z", "location_count": 12, "location_summary": "Gilbert, Arizona • Los Angeles, California • Sacramento, California + 7 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03139370" }, { "nct_id": "NCT05316129", "title": "Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "Follicle Stimulating Hormone Receptor T Cells", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 10, "start_date": "2022-04-28", "completion_date": "2029-05", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-10-05T06:45:57.119Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05316129" }, { "nct_id": "NCT01153646", "title": "Gene Transfer for HIV Using Autologous T Cells", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "pHIV7-shI-TAR-CCR5RZ treated CD4 cells", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 5, "start_date": "2010-04", "completion_date": "2011-01", "has_results": false, "last_update_posted_date": "2011-01-19", "last_synced_at": "2026-10-05T06:45:57.119Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01153646" }, { "nct_id": "NCT05672173", "title": "Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Transformed Chronic Lymphocytic Leukemia", "Refractory Transformed Chronic Lymphocytic Leukemia", "Richter Syndrome" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Lisocabtagene Maraleucel", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pheresis", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2023-06-02", "completion_date": "2027-08-24", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-05T06:45:57.119Z", "location_count": 2, "location_summary": "Duarte, California • New York, New York", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05672173" }, { "nct_id": "NCT01740557", "title": "Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Melanoma", "Stage III Cutaneous Melanoma AJCC v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7" ], "interventions": [ { "name": "Aldesleukin", "type": "BIOLOGICAL" }, { "name": "CXCR2-transduced Autologous Tumor Infiltrating Lymphocytes", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "NGFR-transduced Autologous T Lymphocytes", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2015-01-28", "completion_date": "2023-04-21", "has_results": true, "last_update_posted_date": "2024-10-08", "last_synced_at": "2026-10-05T06:45:57.119Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01740557" }, { "nct_id": "NCT05801913", "title": "Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "High Grade B-Cell Non-Hodgkin's Lymphoma", "Intermediate Grade B-Cell Non-Hodgkin's Lymphoma", "Recurrent B-Cell Non-Hodgkin Lymphoma", "Refractory B-Cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Anti-CD19-CAR CMV-specific T-lymphocytes", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "Lymphodepletion Therapy", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multi-peptide CMV-Modified Vaccinia Ankara Vaccine", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2023-09-29", "completion_date": "2028-12-30", "has_results": false, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-10-05T06:45:57.119Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05801913" } ] }